ARTICLE | Management Tracks
Founder Zang returns to CEO role at I-Mab
Plus: Ho out as CRISPR’s head of R&D, Pfizer’s Hicks named Intellia’ CBO and more
December 21, 2021 3:18 AM UTC
Chairman Jingwu Zang is taking back the CEO role at I-Mab Biopharma (NASDAQ:IMAB) on an acting basis as the cross-border, immuno-oncology and autoimmune disease company prepares to become a commercial organization. I-Mab has also hired former SAB member Andrew Zhu as president to lead the R&D organization; CEO Joan Shen will step down Dec. 31 to pursue other interests.
Zhu, an oncologist who also joins the board, will be based in Shanghai and report to Zang, who founded I-Mab in 2016 and held the CEO title until October 2019. Zhu has worked at Merck & Co. Inc. (NYSE:MRK), Eli Lilly and Co. (NYSE:LLY), Roche (SIX:ROG; OTCQX:RHHBY) and Bayer AG (Xetra:BAYN). ...